For patients with ST-segment elevation myocardial infarction (STEMI), a pharmacoinvasive strategy after fibrinolysis is beneficial for smokers and nonsmokers, according to a study published in the Oct 1 issue of The American Journal of Cardiology.
Nigel S. Tan, MD, from St. Michael’s Hospital in Toronto, and colleagues examined whether the optimal treatment strategy after fibrinolysis differs based on smoking status.
